このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

ADHDの未就学児におけるSPN-812(ビロキサジン持続放出カプセル)の評価

2026年10月2日 更新者:Supernus Pharmaceuticals, Inc.

注意欠陥/多動性障害 (ADHD )

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

調査の概要

詳細な説明

This is a randomized, double-blind, placebo-controlled, multicenter, 2-arm (1:1), parallel-group, efficacy and safety/tolerability fixed-dose study of SPN-812 in preschool-age children (4 to 5 years old) with ADHD. Participants will be screened for eligibility for up to 4 weeks. Eligible participants will be treated with study medication for 6 weeks. The total duration of the study is up to 10 weeks.

研究の種類

介入

入学 (推定)

286

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Alabama
      • Saraland、Alabama、アメリカ、36571
    • Arkansas
      • Fayetteville、Arkansas、アメリカ、72703
        • 引きこもった
        • Preferred Research Partners-NWA, LLC
      • Little Rock、Arkansas、アメリカ、72211
    • California
      • Anaheim、California、アメリカ、92805
        • 募集
        • Advanced Research Center (ARC), Inc.
        • コンタクト:
      • Encino、California、アメリカ、91316
        • 引きこもった
        • Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Encino]
      • Garden Grove、California、アメリカ、92844
        • 終了しました
        • National Institute of Clinical Research (PICR)
      • Imperial、California、アメリカ、92251
        • 募集
        • Sun Valley Research Center
        • コンタクト:
      • Long Beach、California、アメリカ、90807
        • 募集
        • Alliance Research
        • コンタクト:
      • Newport Beach、California、アメリカ、92660
        • 引きこもった
        • Wake Research-Pharmacology Research Institute (WR-PRI), LLC [Newport Beach]
    • Colorado
      • Centennial、Colorado、アメリカ、80112
        • 募集
        • IMMUNOe Research Centers
        • コンタクト:
        • コンタクト:
          • 電話番号:303-773-9000
    • Florida
      • Clermont、Florida、アメリカ、34711
        • 引きこもった
        • Vertex Clinical Research, LLC
      • Coral Gables、Florida、アメリカ、33134
        • 募集
        • Luna Research Center
        • コンタクト:
          • 電話番号:305-613-7761
      • Gainesville、Florida、アメリカ、32607
        • 終了しました
        • Sarkis Clinical Trials
      • Jacksonville、Florida、アメリカ、32256
        • 募集
        • Clinical Neuroscience Solutions, Inc.
        • コンタクト:
          • 電話番号:904-281-5757
      • Lakeland、Florida、アメリカ、33803
        • 終了しました
        • Accel Research Sites - Lakeland CRU
      • Miami、Florida、アメリカ、33155
      • Orange City、Florida、アメリカ、32763
        • 募集
        • Medical Research Group of Central Florida
        • コンタクト:
          • 電話番号:386-775-7627
      • Orlando、Florida、アメリカ、32801
        • 募集
        • Clinical Neuroscience Solutions, Inc.
        • コンタクト:
      • Orlando、Florida、アメリカ、32803
        • 募集
        • APG Research LLC
        • コンタクト:
        • コンタクト:
          • 電話番号:165 407-423-7149
      • Tamarac、Florida、アメリカ、33321
        • 募集
        • D&H Tamarac Research Center
        • コンタクト:
      • Virginia Gardens、Florida、アメリカ、33166
      • Winter Park、Florida、アメリカ、32789
    • Georgia
      • Atlanta、Georgia、アメリカ、30328
        • 募集
        • Clinical Integrative Research Center of Atlanta
        • コンタクト:
          • 電話番号:678-705-7341
      • Atlanta、Georgia、アメリカ、30318
        • 募集
        • Advanced Discovery Research LLC
        • コンタクト:
      • Decatur、Georgia、アメリカ、30030
        • 募集
        • CenExcel iResearch, LLC
        • コンタクト:
          • 電話番号:404-537-1281
      • Savannah、Georgia、アメリカ、31405
        • 募集
        • CenExel iResearch, LLC.
        • コンタクト:
          • 電話番号:912-744-0800
    • Indiana
      • Evansville、Indiana、アメリカ、47715
        • 終了しました
        • Qualmedica Research, LLC.
    • Kentucky
      • Bardstown、Kentucky、アメリカ、40004
        • 募集
        • Kentucky Pediatric/Adult Research
        • コンタクト:
      • Owensboro、Kentucky、アメリカ、42301
        • 終了しました
        • Qualmedica Research, LLC.
    • Louisiana
      • New Orleans、Louisiana、アメリカ、70115
        • 終了しました
        • DelRicht Research (Touro Medical Center)
      • Prairieville、Louisiana、アメリカ、70769
        • 募集
        • DelRicht Research
        • コンタクト:
    • Maryland
      • Baltimore、Maryland、アメリカ、21205
        • 募集
        • Kennedy Krieger Institute
        • コンタクト:
          • 電話番号:443-923-3850
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02445
        • 募集
        • Boston Children's Hospital
        • コンタクト:
          • 電話番号:617-919-6954
        • コンタクト:
    • Michigan
      • Bloomfield Hills、Michigan、アメリカ、48302
        • 募集
        • Neurobehavioral Medicine Group
        • コンタクト:
    • Mississippi
      • Flowood、Mississippi、アメリカ、39232
        • 募集
        • Precise Research Centers
        • コンタクト:
          • 電話番号:601-420-5812
    • Nevada
      • Las Vegas、Nevada、アメリカ、89128
        • 募集
        • Clinical Research of Southern Nevada, LLC.
        • コンタクト:
    • New Jersey
      • Berlin、New Jersey、アメリカ、08009
        • 引きこもった
        • Hassman Research Institute
      • Irvington、New Jersey、アメリカ、07111
      • Neptune City、New Jersey、アメリカ、07753
        • 募集
        • Jersey Shore University Medical Center
        • コンタクト:
    • New York
      • New York、New York、アメリカ、10028
        • 引きこもった
        • Icahn School of Medicine at Mount Sinai
    • North Carolina
      • Durham、North Carolina、アメリカ、27705
        • 募集
        • Duke University
        • コンタクト:
          • 電話番号:919-681-1100
    • Ohio
      • Cincinnati、Ohio、アメリカ、45229
        • 募集
        • Cincinnati Children's Hospital and Medical Center
        • コンタクト:
      • West Chester、Ohio、アメリカ、45069
        • 引きこもった
        • CincyScience
    • Oregon
      • Gresham、Oregon、アメリカ、97030
        • 募集
        • Cyn3rgy Research
        • コンタクト:
    • Pennsylvania
      • Hershey、Pennsylvania、アメリカ、17033
        • 募集
        • Penn State Health Medical Group - Psychiatry and Behavioral Health
        • コンタクト:
        • コンタクト:
          • 電話番号:717-531-5656
    • South Carolina
      • North Charleston、South Carolina、アメリカ、29405
      • Summerville、South Carolina、アメリカ、29486
    • Tennessee
      • Memphis、Tennessee、アメリカ、38119
        • 募集
        • Clinical Neuroscience Solutions, Inc.
        • コンタクト:
          • 電話番号:901-843-1045
    • Texas
      • Bellaire、Texas、アメリカ、77401
        • 引きこもった
        • Houston Clinical Trials, LLC.
      • Dallas、Texas、アメリカ、75230
        • 終了しました
        • Javara
      • Plano、Texas、アメリカ、75093
        • 募集
        • AIM Trials, LLC
        • コンタクト:
        • コンタクト:
          • 電話番号:214-856-2778
      • The Woodlands、Texas、アメリカ、77381
        • 募集
        • Family Psych of The Woodlands
        • コンタクト:
    • Virginia
      • Petersburg、Virginia、アメリカ、23805
      • Richmond、Virginia、アメリカ、23220
        • 募集
        • Virginia Commonwealth University, Virginia Treatment Center for Children
        • コンタクト:
          • 電話番号:804-628-8736

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

4年~5年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Is male or female 4 years 0 months of age to less than or equal to 5 years 9 months of age at Visit 1 (Screening) and considered medically healthy.
  2. Subject's parent(s) or legal guardian(s)/representative(s) is (are) willing and able to provide written informed consent before completing any study related procedures.
  3. Has a primary diagnosis of ADHD according to DSM-IV-TR criteria and confirmed with the Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime Version (K-SADS-PL).
  4. Has an ADHD-RS-IV-P Total Score of ≥ 28 (males) or ≥ 24 (females) at Visit 1 (Screening) and at Visit 2 (Baseline).
  5. Has a CGI-S score of ≥ 4 (moderate or worse) at Visit 1 (Screening) and at Visit 2 (Baseline).
  6. Has undergone an adequate course of non-pharmacologic treatment or is having symptoms severe enough to warrant pharmacologic treatment without prior non-pharmacologic treatment.
  7. Is participating in a structured group activity (e.g., preschool, kindergarten, sports, Sunday school, summer camp or childcare program) at least 2 days a week during study so as to assess symptoms and impairment in a setting outside the home.
  8. Has not initiated any behavioral intervention/therapy within 30 days of Visit 1 (Screening) and does not plan to initiate any new or discontinue any ongoing behavioral intervention/therapy during the study (e.g., subject is eligible if behavioral intervention/therapy is initiated 30 or more days prior to Visit 1 [Screening] and continues with a similar duration/frequency throughout their study).
  9. Subjects who are on ADHD medication at Visit 1 (Screening), but whose ADHD symptoms are not well controlled on current ADHD medication (e.g., meets Inclusion Criterion #4), meet all other inclusion/exclusion criteria, and discontinues ADHD medication at least 7 days prior to the day of Visit 2 (Baseline) are eligible to participate.
  10. Has no current condition in the opinion of the Investigator that could confound efficacy assessments, safety assessments or increase participant risk.
  11. Has lived with the same parent(s) or legal guardian(s) or has lived under a shared living arrangement (e.g., joint legal custody) for greater than or equal to 6 months prior to Visit 1 (Screening).
  12. Has a body weight ≥5th percentile for age and sex at Visit 1 (Screening) and Visit 2 (Baseline).

Exclusion Criteria:

  1. Has a diagnosis at Screening (per K-SADS-PL) of another psychiatric disorder that is considered to be the primary diagnosis rather than ADHD or has a comorbid psychiatric disorder secondary to ADHD that, in the opinion of the investigator (after consulting medical monitor), will likely interfere with study treatment adherence and/or impact study results.
  2. Has a current diagnosis of a major neurological disorder. The eligibility of those who have seizures, a history of seizure-like events (e.g., syncope, myoclonus, severe muscle spasms), a family history of seizure disorder (immediate family, i.e., sibling, parent), and/or febrile seizures will be assessed on a case-by-case basis after consulting the medical monitor.
  3. History of Bipolar Disorder diagnosed in a first degree relative.
  4. Has global development delay or intellectual disability by medical history.
  5. Has a current diagnosis of a significant (per Investigator's evaluation and/or judgement) systemic disease.
  6. Has body mass index > 95th percentile for the subject's age and sex at Visit 1 (Screening) or Visit 2 (Baseline).
  7. Has a mean resting systolic and diastolic blood pressure* that are both >95th percentile for age sex, and height and has a mean resting pulse rate* that is >95th percentile for age and sex (males: >117 bpm; females: >122 bpm) at Visit 1 (Screening) or Visit 2 (Baseline). * Note: The mean of three measurements while seated.
  8. Has a clinically significant electrocardiogram finding(s) at Visit 1 (Screening).
  9. Is currently taking SPN-812 for ADHD, has previously taken SPN-812 for ADHD, but discontinued due to a lack of efficacy or adverse reactions, or has history of allergic reaction, hypersensitivity or intolerance to viloxazine.
  10. Has an allergy to or cannot swallow pudding and applesauce and cannot swallow intact capsule whole.
  11. Has any food allergy, intolerance, restriction or special diet that, in the opinion of the Investigator, could contraindicate the subject's participation in the study.
  12. Has received any investigational drug within the longer of 30 days or 5 half-lives prior to Visit 2 (e.g., first dose of study medication).
  13. Has a positive urine drug test at Visit 1 (Screening). A positive test for amphetamines is allowed for subjects receiving a stimulant ADHD medication at Screening. The subject will be required to discontinue the stimulant for the duration of the study, beginning at least 7 days prior to Visit 2 (Baseline).
  14. Is using of prohibited concomitant medications including known CYP1A2 substrates (e.g., theophylline, melatonin) during the Screening Period or (anticipated) for the duration of the study.
  15. Any reason that, in the opinion of the Investigator, would prevent the subject from participating in the study.
  16. Has suicidal ideation ("Yes" indicated on C-SSRS question 4 or 5) or suicidal behavior ("Yes" indicated on C-SSRS for any suicidal behavior) within 6 months prior to or the day of Visit 1 (Screening) or has attempted suicide ("Yes" indicated on C-SSRS for lifetime).

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター:Placebo

Placebo, qd

Placebo will be administered once daily

実験的:SPN-812

SPN-812, qd

100mg SPN-812 will be administered once daily and compared to Placebo

他の名前:
  • SPN-812

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline in the Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Total Score at End of Study (Week 6)
時間枠:Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I", 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the ratings of all 18 items yields the raw Total score (range: 0-54; the higher the Total score, the more severe the ADHD symptoms). Post-baseline raw Total scores are converted to a change from baseline Total score. A lower change from baseline ADHD-RS-IV-P Total Score (<0) represents a better outcome.

Baseline and Week 6

二次結果の測定

結果測定
メジャーの説明
時間枠
Change from Baseline in the Clinical Global Impression of Severity (CGI-S) Score at End of Study (Week 6)
時間枠:Baseline and Week 6

The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients (the higher the score, the more severe the overall ADHD symptoms). Post-baseline (raw) CGI-S scores are converted to a change from baseline score. A lower change from baseline CGI-S score (<0) represents a better outcome.

Baseline and Week 6
Clinical Global Impression of Change (CGI-C) Score at End of Study (Week 6)
時間枠:Week 6

The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". A CGI-C score <4 represents a better outcome.

Week 6
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Hyperactivity/Impulsivity Subscale Score at End of Study (Week 6)
時間枠:Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine H/I items yields the raw H/I subscale score (range: 0-27; the higher the H/I subscale score, the more severe the H/I symptoms). Post-baseline raw H/I subscale scores are converted to a change from baseline score. A lower change from baseline H/I subscale score (<0) represents a better outcome.

Baseline and Week 6
Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Inattention Subscale Score at End of Study (Week 6)
時間枠:Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two subscales: inattention ("IA", 9 items) and hyperactivity-impulsivity ("H/I" 9 items).The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale, where 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. The sum of the nine IA items yields the raw IA subscale score (range: 0-27; the higher the IA subscale score, the more severe the IA symptoms). Post-baseline raw IA subscale scores are converted to a change from baseline score. A lower change from baseline IA subscale score (<0) represents a better outcome.

Baseline and Week 6
Clinical Global Impression of Severity (CGI-S) Responder Rate (percentage of subjects with CGI-S score of 1 or 2) at End of Study (Week 6)
時間枠:Baseline and Week 6

The Clinical Global Impression of Severity (CGI-S) is a single item clinician-rated assessment of the severity of subject's condition (ADHD symptoms) in relation to the clinician's total experience with patients with ADHD. The CGI-S is evaluated on a 7-point scale with 1 = Normal, not at all ill, asymptomatic, 2 = Borderline Ill, 3 = Mildly Ill, 4 = Moderately Ill, 5 = Markedly Ill, 6 = Severely Ill, and 7 = Among the most extremely ill patients. The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders".

Baseline and Week 6
Clinical Global Impression of Change (CGI-C) Responder Rate (percentage of subjects with CGI-C score of 1 or 2) at End of Study (Week 6)
時間枠:Week 6

The Clinical Global Impression of Change (CGI-C) is a single item clinician-rated assessment of how much the subject's condition (ADHD) has improved, worsened or has not changed relative to his/her baseline state prior to the beginning of treatment. The CGI-C is rated on a 7-point scale from 1 to 7, where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse", 6 = "much worse", and 7 = "very much worse". The responder rate (percent) is calculated by dividing "the number of 'responders' (m)" by "the number of subjects analyzed at the respective Visit/Week (n)" and multiplying the product by 100. Responder Rate values range from 0 to 100%. A percent >50% represents a greater number of "responders" versus "non-responders".

Week 6
Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) Responder Rate (percentage of subjects with ≥ 50% Reduction in Change from Baseline) at End of Study (Week 6)
時間枠:Baseline and Week 6

The Attention-Deficit/Hyperactivity Disorder Rating Scale, 4th Edition, Preschool Version (ADHD-RS-IV-P) consists of 18 items that correspond directly to the DSM-IV-TR criteria for ADHD. The scale is subdivided into two 9 item subscales: inattention and hyperactivity-impulsivity. The clinician rates the frequency and severity of each symptom on a 4-point Likert-type scale; 0 = Never or rarely, 1 = Sometimes, 2 = Often, and 3 = Very often. Sum of 18 ratings yields the Total score (range: 0-54; higher score represents severer symptoms). Percent reduction is calculated for the ADHD-RS-IV-P score: [("Post-baseline"-"Baseline")/"Baseline"] x 100; range: 0 to 100%; a "responder" is a subject with a 50% or greater reduction in change from baseline Total score. Responder rate (percent of responders) is calculated: ["number of 'responders' (m)"/ "number of subjects analyzed" (n)] X 100; range: 0 to 100%. A Responder Rate greater than 50%, represents more "responders" versus "nonresponders".

Baseline and Week 6

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディディレクター:Joseph Hull, PhD、Supernus Pharmaceuticals, Inc.

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年3月19日

一次修了 (推定)

2028年1月1日

研究の完了 (推定)

2028年1月1日

試験登録日

最初に提出

2021年2月26日

QC基準を満たした最初の提出物

2021年3月1日

最初の投稿 (実際)

2021年3月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月5日

QC基準を満たした最後の更新が送信されました

2026年10月2日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

キーワード

その他の研究ID番号

  • 812P401

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する